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To the Editor: Gonçalves and El Nahas [1] raise interesting
comments on our publication describing how blockade of
the angiotensin I receptor with losartan increases serum
potassium which is, in turn, associated with an increased
risk of renal outcomes in patients with diabetes and
nephropathy [2]. In their letter, Gonçalves and El Nahas
suggest that those patients who developed hyperkalaemia
were more likely to have pre-existing glomerular or
tubulointerstitial damage, which could have accounted for
the faster progression of renal disease. Although this could,
to a certain extent, hold true, we believe that such a theory
does not explain our findings.
We performed various analyses to ensure that the
relationship between increased serum potassium and renal
outcome was independent of the severity of the underlying
renal disease. First, we corrected for various renal risk
markers, most notably the baseline and change in estimated
glomerular filtration rate. Second, we conducted a pair-
matched analysis selecting patients with similar character-
istics who did and did not develop hyperkalaemia. Both
analyses consistently showed that participants in whom
serum potassium levels rose had a higher risk of renal
disease. We therefore consider it unlikely that the greater
degree of pre-existing renal injury in individuals who
developed high serum potassium levels is the main factor
responsible for their higher renal risk. Nevertheless, since
neither glomerular nor tubulointerstitial damage was
measured in the Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan (RENAAL) trial,
we cannot completely rule out the possibility that
individuals who developed hyperkalaemia also had pre-
existing renal damage.
Further indirect evidence to support our hypothesis that
the increase in serum potassium is associated with renal
outcome stems from an additional analysis showing that
adjustment of the losartan treatment effect for the residual
potassium level (the serum potassium level during treat-
ment) improves the overall renoprotective response to
losartan. These data suggest that the increase in serum
potassium during losartan therapy attenuates its long-term
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of hyperkalaemia may result in a better renal outcome. As
mentioned by Gonçalves and El Nahas [1], it could still be
possible that individuals who experienced high serum
potassium levels received a higher dose of losartan. This
hypothesis is, however, less likely because the dose of
losartan was titrated towards 100 mg/day in almost all
patients. Gonçalves and El Nahas also suggested that those
patients who experienced high serum potassium levels
could have been more sensitive to a similar dose of losartan
[1]. Nevertheless, this does not negate the fact that the
development of high potassium levels appears to offset the
renoprotective effect of losartan.
Given that both the short-term responses to losartan in
terms of serum potassium levels and albuminuria are
associated with renal outcomes, either positively (albumin-
uria) or negatively (potassium), Gonçalves and El Nahas [1]
highlight the importance of evaluating the relationship
between both of these responses within individual patients.
Such a question is of clinical relevance since these
opposing responses in individual patients may offer
important insight into their ultimate renal outcome. In this
regard, we performed additional analyses to investigate
possible correlations between responses in serum potassium
levels and albuminuria within each individual patient in the
RENAAL trial. The majority of patients (52.6%) showed a
decrease in albuminuria and increase in serum potassium
levels during treatment with losartan. However, a substan-
tial number of patients experienced either reductions in
both albuminuria and serum potassium levels (17.7%), an
increase in albuminuria and a decrease in serum potassium
levels (9.6%), or an increase in both variables (20.0%).
These data illustrate that the change in two variables in
response to a single drug varies within an individual. The
group of patients in whom both albuminuria and serum
potassium rose, and thus had high residual albuminuria and
high serum potassium levels during losartan therapy, had a
very high risk of renal events, as shown in Fig. 1. However,
our findings are based on a post hoc analysis, and a
prospective evaluation is needed to prove that manipulation
of serum potassium levels during angiotensin receptor
blocker (ARB) therapy may result in improved renal
outcomes. Nevertheless, these data clearly support the need
for monitoring and optimising the response of serum
potassium levels and albuminuria in individual patients to
improve the long-term renal protective effects of ARBs.
Based on our observation that losartan treatment is
associated with an increase in serum potassium levels,
which increases renal risk, should we reconsider the
continued use of inhibitors of the renin–angiotensin–
aldosterone system (RAAS)? Gonçalves and El Nahas [1]
indeed question the use of RAAS inhibitors and refer to the
recent Ongoing Telmisartan Alone and in Combination with
Ramipril Trial (ONTARGET), which showed increases in
renal risk and hyperkalaemic events associated with
combined angiotensin-converting enzyme inhibitor (ACEI)
and ARB therapy compared with the single use of these
agents [3]. However, given the proven renal and cardiovas-
cular protective effects of ACEIs and ARBs in various
populations (including those with diabetes and nephropa-
thy) [4, 5], we strongly discourage the discontinuation of
these agents. Instead, strategies to optimise the effect of a
drug on the good surrogates, such as blood pressure and
albuminuria, and to minimise its effect on the bad
surrogates, such as serum potassium, are recommended. This
approach may attenuate the high renal risk of the growing
population of patients with diabetes and nephropathy.
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Fig. 1 Risk for renal events by mean levels of albuminuria (ACR)
and serum potassium during follow-up. The figure shows that both the
residual albuminuria and serum potassium determine the renal
outcome. ACR, albumin to creatinine ratio. For conversion of ACR
to mg/g, multiply by 8.84
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